Fig. 1

Kaplan‒Meier analysis of the OS (A) and PFS (B) in patients with primary DLBCL treated with prophylactic anti-HBV therapy with entecavir and tenofovir after June 17, 2014.OS: overall survival; PFS: progression-free survival; DLBCL: diffuse large B-cell lymphoma; HBV: hepatitis B virus